Gensight Biologics SA (SIGHT) - Total Assets
Based on the latest financial reports, Gensight Biologics SA (SIGHT) holds total assets worth €8.26 Million EUR (≈ $9.65 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Gensight Biologics SA - Total Assets Trend (2012–2025)
This chart illustrates how Gensight Biologics SA's total assets have evolved over time, based on quarterly financial data. Also see market value of Gensight Biologics SA for the company's overall valuation and market capitalisation.
Gensight Biologics SA - Asset Composition Analysis
Current Asset Composition (December 2025)
Gensight Biologics SA's total assets of €8.26 Million consist of 60.3% current assets and 39.7% non-current assets. Review Gensight Biologics SA total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 29.3% |
| Accounts Receivable | €1.58 Million | 19.1% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €427.00K | 5.2% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Gensight Biologics SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Gensight Biologics SA (SIGHT) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gensight Biologics SA's current assets represent 60.3% of total assets in 2025, a decrease from 88.6% in 2012.
- Cash Position: Cash and equivalents constituted 29.3% of total assets in 2025, down from 31.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 19.1% of total assets.
Gensight Biologics SA Competitors by Total Assets
Key competitors of Gensight Biologics SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Genscript Biotech Corporation
F:G51
|
Germany | €4.85 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
89bio Inc
NASDAQ:ETNB
|
USA | $603.49 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.78 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
Gensight Biologics SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.39 | 0.24 | 2.56 |
| Quick Ratio | 0.39 | 0.24 | 2.26 |
| Cash Ratio | 0.00 | 0.00 | 2.22 |
| Working Capital | €-7.69 Million | €-17.27 Million | €26.64 Million |
Gensight Biologics SA - Advanced Valuation Insights
This section examines the relationship between Gensight Biologics SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 30.41 |
| Latest Market Cap to Assets Ratio | 3.16 |
| Asset Growth Rate (YoY) | -23.2% |
| Total Assets | €8.26 Million |
| Market Capitalization | $26.12 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Gensight Biologics SA's assets at a significant premium (3.16x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Gensight Biologics SA's assets decreased by 23.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Gensight Biologics SA (2012–2025)
The table below shows the annual total assets of Gensight Biologics SA from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €8.26 Million ≈ $9.65 Million |
-23.24% |
| 2024-12-31 | €10.76 Million ≈ $12.57 Million |
+17.78% |
| 2023-12-31 | €9.13 Million ≈ $10.68 Million |
-64.80% |
| 2022-12-31 | €25.94 Million ≈ $30.33 Million |
-54.21% |
| 2021-12-31 | €56.65 Million ≈ $66.23 Million |
+19.61% |
| 2020-12-31 | €47.36 Million ≈ $55.37 Million |
+45.80% |
| 2019-12-31 | €32.48 Million ≈ $37.98 Million |
-12.16% |
| 2018-12-31 | €36.98 Million ≈ $43.23 Million |
-40.56% |
| 2017-12-31 | €62.21 Million ≈ $72.73 Million |
+5.03% |
| 2016-12-31 | €59.23 Million ≈ $69.25 Million |
+63.12% |
| 2015-12-31 | €36.31 Million ≈ $42.45 Million |
+145.07% |
| 2014-12-31 | €14.82 Million ≈ $17.32 Million |
-21.49% |
| 2013-12-31 | €18.87 Million ≈ $22.06 Million |
+31033.60% |
| 2012-12-31 | €60.62K ≈ $70.87K |
-- |
About Gensight Biologics SA
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV… Read more